Gamma knife radiosurgery for the treatment of recurrent seizures after incomplet...

Collect this paper and discover other ones on Labmeeting. Learn more.
- Hide Abstract
To evaluate the efficacy and safety of gamma knife radiosurgery (GKS) in treating temporal lobe epilepsy, GKS was performed in four adult patients with recurrent complex partial seizures who underwent incomplete anterior temporal lobectomy (ATL) but were reluctant to undergo a second resective surgery. A marginal dose of 24.5-25Gy, corresponding to 65-70% isodose curve, was delivered to the treatment target that included the residual amygdala and the head and anterior body of the hippocampus. None of the patients had severe acute side effects but three patients had radiation-induced MRI signal changes around the target volume 13, 20, and 24 months after GKS, respectively. All four patients had significant seizure reduction during the first 6-month period and clinical efficacy persisted throughout the 2-year follow-up period. All of the patients also had improved neuropsychological profiles, including memory function and quality-of-life, compared to their pre-GKS conditions. In conclusion, the safety and clinical efficacy of GKS make it a reasonable and suitable therapeutic alternative for patients with recurrent seizures after incomplete ATL. A higher marginal dose of >25Gy and wider coverage may be more clinically beneficial but warrant further investigation.
Seizure : the journal of the British Epilepsy Association 18(7):511-4, 2009 Sep - Who cited this? | PubMed ID: 19505832 | Fulltext


+ Click Here for Related Papers

Join Labmeeting

  • Organize and search your PDF collection
  • Collect papers
  • Search millions of papers
  • Keep up to date with paper alerts
  • Read your papers from anywhere
  • Recommend papers to colleagues
  • Manage your lab

Join Labmeeting

Labmeeting is a web service for researchers. Sign up with your academic email address.

Individuals or corporations not affiliated with an academic institution can request a trial subscription.